On February 25, 2025, SciSparc Ltd. signed an agreement to sell its shares in MitoCareX to N2OFF, resulting in a cash payment of $700,000 and a 16.75% equity stake in N2OFF. This deal is pending stockholder approval and has additional milestones for more shares until December 31, 2028.